Xeljanz 5 MG tablet UU 60S
Ended Awarded
- Contract number
- SPE2DB25FFPFQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,013
Award facts
- Contract value 100% obligated
- $3,012.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,012.98 to AmerisourceBergen Drug Corp for the supply of XELJANZ 5 MG tablets (60-count units). This competitively awarded, firm fixed-price contract with no set-aside designation was issued on August 11, 2025, with an ultimate completion date of August 12, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026, which serves as a comprehensive pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for federal medical procurement needs supporting military and veteran healthcare systems. The company maintains an extensive portfolio of pharmaceutical deliveries across multiple therapeutic domains, with all reviewed contract awards demonstrating competitive procurement through open competition. XELJANZ (tofacitinib) is an immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions, reflecting the company's role in supplying specialty medications to support Defense Health Agency and other government healthcare system requirements. The DLA's Pharmaceutical Prime Vendor Global Program is planning to establish Generation V contracts with multiple regional awards, positioning AmerisourceBergen to continue serving as a key supplier within this strategic framework.
Quick answers
Who was awarded contract SPE2DB25FFPFQ?
SPE2DB25FFPFQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 11, 2025.
How much is contract SPE2DB25FFPFQ worth?
The government has obligated $3,013 on SPE2DB25FFPFQ.
Is contract SPE2DB25FFPFQ an order under another contract?
Yes. SPE2DB25FFPFQ is a delivery order under SPE2DB24D3013, an indefinite delivery contract.
Was contract SPE2DB25FFPFQ competed?
The extent of competition for SPE2DB25FFPFQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award